NEW YORK, May 1 – Variagenics reported Monday an 11-fold increase in first-quarter revenues to $1.1 million from $100,000 in the year-ago quarter.
Revenues stemmed from the company’s new collaboration on pharmacogenomics with Amgen, as well as its continuing collaborations with Boeringher Ingelheim and Isis Pharmaceuticals.